The AML Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning

The AML Channel on VJHemOnc is supported by Curis Inc., GlycoMimetics and Jazz Pharmaceuticals The supporters have no influence over the production of the content.

Latest Videos The AML Sessions Conferences e-Learning Presentations Topics Podcasts Features Expert Editorial Board

Welcome to The Acute Myeloid Leukemia (AML) Channel

VJHemOnc brings you the latest and greatest global advances related to the classification, diagnosis, treatment, and management of AML. Speaking with world-leading experts, The AML Channel delivers video interviews, podcasts, roundtable discussions and more.

Hot topics frequently covered on The AML Channel include the use of measurable residual disease (MRD) testing to guide treatment, antibody-based treatments and CAR-T cell therapies.

Conferences

EBMT 2023
ISAL 2023
Tandem Meetings 2023
CAR-T Meeting 2023
ASH 2022
SOHO 2022
1:33
The impact of novel targeted & immune therapies in leukemia
Norbert-Claude Gorin • 23 Apr 2023
1:23
Indications for autologous stem cell transplantation in AML
Norbert-Claude Gorin • 23 Apr 2023
1:39
The impact of complex karyotype on post-transplant outcomes in NPM1-mutated AML
Nour Moukalled • 25 Apr 2023
1:21
The challenge of age in SCT & cellular therapy, and introducing cellular therapy in earlier LOT
Didier Blaise • 24 Apr 2023
View All Videos
1:26
The current role of MRD in AML and challenges with implementing this in clinical practice
Thomas Cluzeau • 20 Mar 2023
3:25
Personalizing therapy in AML: current status and future outlooks
Marina Konopleva • 20 Mar 2023
8:05
Using AI to segment and classify bone marrow cells in patients with AML
Philippe Leleux • 23 Mar 2023
1:20
The prognostic value of CD34+CD38- leukemic stem cell frequency in AML
Jacqueline Cloos • 20 Mar 2023
View All Videos
3:46
Patient selection for SCT & recent updates in strategies to reduce GvHD & relapse following SCT
Dietger Niederwieser • 21 Feb 2023
3:34
Clofarabine preconditioning followed by allogeneic transplantation with TBI & PTCy for R/R AML
Seema Naik • 22 Feb 2023
5:14
Global trends in the use of stem cell transplantation for AML
Molly Tokaz • 2 Mar 2023
3:49
Challenges in finding a stem cell transplant donor in ethnic and racial minorities
Molly Tokaz • 2 Mar 2023
View All Videos
1:27
IL3-zetakine coupled to a CD33 costimulatory receptor as a dual-targeting CAR approach in AML
Vincenzo Perriello • 10 Feb 2023
2:08
Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cells
Sascha Haubner • 10 Feb 2023
8:18
CAR-T therapy in acute and chronic leukemias: where are we now and where are we heading?
John Gribben • 10 Feb 2023
View All Videos
1:37
A Phase II trial evaluating E7820 in patients with AML with splicing factor mutations
Eytan Stein • 12 Dec 2022
1:31
The safety and efficacy of revumenib in patients with KMT2A-rearranged or NPM1-mutated AML
Eytan Stein • 12 Dec 2022
1:18
Beat AML Master sub-study: enasidenib and response-driven addition of azacitidine in IDH2m AML
Eytan Stein • 12 Dec 2022
1:12
CPX-351 and gemtuzumab ozogamicin in R/R AML and MDS
Jayastu Senapati • 11 Dec 2022
View All Videos
5:22
Determining the optimal dose of induction therapy for patients with AML
Selina Luger • 6 Oct 2022
3:26
Implications of RAS mutational status in subsets of patients with newly diagnosed AML
Tapan Kadia • 29 Sep 2022
5:05
Determining the most suitable consolidation therapies for AML by defining patient risk group
Selina Luger • 6 Oct 2022
2:55
The importance of FLT3 inhibitors in AML and factors to consider when choosing between these agents
Tapan Kadia • 29 Sep 2022
View All Videos

Topics

MRD
Transplant
CAR-T & Cellular Therapy
Real-World Data
Trial Updates
Immuno-Oncology
3:12
Should we delay transplantation in patients with standard-risk multiple myeloma?
Paul Richardson • 12 May 2023
1:23
Indications for autologous stem cell transplantation in AML
Norbert-Claude Gorin • 23 Apr 2023
0:54
Clinical responses of pediatric patients with R/R acute leukemia treated with aza/ven
Sarah Tasian • 16 Apr 2023
1:31
The safety and efficacy of revumenib in patients with KMT2A-rearranged or NPM1-mutated AML
Eytan Stein • 12 Dec 2022
View All Videos
4:28
Approaching patients with MDS and AML who relapse after alloSCT & strategies to prevent relapse
Pramila Krishnamurthy • 24 Apr 2023
2:06
Distinguishing and choosing between intensive and non-intensive therapies for patients with HR-MDS
Uwe Platzbecker • 11 May 2023
3:12
Should we delay transplantation in patients with standard-risk multiple myeloma?
Paul Richardson • 12 May 2023
1:33
The impact of novel targeted & immune therapies in leukemia
Norbert-Claude Gorin • 23 Apr 2023
View All Videos
1:33
The impact of novel targeted & immune therapies in leukemia
Norbert-Claude Gorin • 23 Apr 2023
10:17
Updates in AML
David Sallman et al. • 1 Jan 1970
1:21
The challenge of age in SCT & cellular therapy, and introducing cellular therapy in earlier LOT
Didier Blaise • 24 Apr 2023
1:30
Insights into NKG2D-targeting CAR-T cells in R/R AML
David Sallman • 20 Mar 2023
View All Videos
3:13
Validation of 2022 diagnostic & prognostic classifications of AML
Enrico Attardi • 21 Mar 2023
5:14
Global trends in the use of stem cell transplantation for AML
Molly Tokaz • 2 Mar 2023
3:49
Challenges in finding a stem cell transplant donor in ethnic and racial minorities
Molly Tokaz • 2 Mar 2023
1:23
The role of MRD status & the ELN 2022 in predicting clinical outcomes of patients with AML
Eunice Wang • 12 Dec 2022
View All Videos
1:02
TakeAim Leukemia: positive interim results regarding the efficacy of emavusertib in HR-MDS and AML
Uwe Platzbecker • 11 May 2023
0:49
Treatment avenues for patients with R/R FLT3-mutated AML: optimizing FLT3 inhibitors
Paresh Vyas • 24 Apr 2023
5:02
Results from AGILE: ivosidenib-azacitidine vs azacitidine-placebo in patients with IDH1m AML
Vidhya Murthy • 19 May 2023
4:28
Approaching patients with MDS and AML who relapse after alloSCT & strategies to prevent relapse
Pramila Krishnamurthy • 24 Apr 2023
View All Videos
3:31
Promising treatment options emerging for higher-risk MDS & the value of clinical trials
Pramila Krishnamurthy • 24 Apr 2023
4:28
Approaching patients with MDS and AML who relapse after alloSCT & strategies to prevent relapse
Pramila Krishnamurthy • 24 Apr 2023
1:33
The impact of novel targeted & immune therapies in leukemia
Norbert-Claude Gorin • 23 Apr 2023
10:17
Updates in AML
David Sallman et al. • 1 Jan 1970
View All Videos

The AML Channel on VJHemOnc is supported by Curis Inc., GlycoMimetics and Jazz Pharmaceuticals

The supporters have no influence over the production of the content.

If you are interested in becoming a supporter of the AML Channel, please contact us.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals